ECCO Position Statements are a publication category complementary to ECCO Guidelines. They address areas of great importance for the IBD Community. Topic selection as well as the agreed workflow are therefore subject to ECCO Governing Board decisions. These publications are subjective assessments and can be supported by a survey and/or a voting procedure. The authors group should moreover include representatives of relevant ECCO Committees.
|
Topics |
Publication |
|
The Use of Biosimilar Medicines in the Treatment of IBD |
August 2013 |
|
The Use of Biosimilars for IBD - an Update |
December 2016 |
|
ECCO IBD Curriculum |
January 2017 |
|
Quality of Care Standards in IBD |
February 2020 |
|
Harmonisation of the Approach to UC Histopathology |
June 2020 |
|
IBD Management During the COVID-19 Outbreak: The Ten Do’s and Don’ts from the ECCO-COVID Taskforce |
July 2020 |
|
Development of a Core Outcome Set for Real-world Data in IBD |
Early 2022 |
|
Harmonisation of Crohn’s disease mucosal Histopathology |
Early 2022 |
|
Definitions of histological abnormalities in IBD |
January 2023 |